An Open Letter to Our Stakeholders
As we close another year, it’s important to reflect on our journey and the exciting road ahead for RespireRx Pharmaceuticals Inc. and its subsidiaries, EndeavourRx LLC and ResolutionRx Ltd. In this letter, we aim to summarize our achievements in tackling the complexities of neuronal signaling disorders, share our strategies, and outline our aspirations for 2026.
Current Achievements and Future Aspirations
In the past year, we've navigated various financial challenges, but we've also celebrated significant successes, particularly in our scientific endeavors. Numerous studies from 2025 have been published in respected journals, emphasizing our contributions to the field and garnering attention from fellow researchers.
To push forward, our strategy includes enhancing our research capabilities and maintaining a pipeline focused on developing treatments targeting obstructive sleep apnea (OSA) and attention deficit hyperactivity disorder (ADHD). We believe our proactive approach will lead to tangible outcomes and meaningful improvements in patients' lives.
Strategic Restructuring to Enhance Clinical Development
ResolutionRx Ltd was established to foster innovation in Australia. This wholly-owned public company has enrolled in the Australian research and development tax incentive program, allowing us to recover a substantial portion of qualified expenditures as we advance our pipeline focused on the endocannabinoid system. Plans are underway for an equity financing to support our ongoing projects.
EndeavourRx LLC, created as a private entity, is focused on developing promising compounds like AMPAkines and GABAkines. These positive allosteric modulators are designed to enhance neurotransmitter activity and show potential in treating various neurological conditions.
AMPAkines and Their Impact
Traumatic spinal cord injuries lead to numerous complications, including neurogenic bladder dysfunction, adversely affecting quality of life. Thankfully, our research into AMPAkines has gained traction, as evidenced by a grant awarded for clinical trials regarding CX1739 aimed at improving bladder function in patients with spinal cord injuries. This collaboration with the Shirley Ryan AbilityLab reinforces our commitment to scientific research.
GABAkines and Their Efficacy
On the glimmering horizon of our development efforts is KRM-II-81, our lead GABAkine, which has demonstrated remarkable anti-seizure activity in challenging preclinical studies. Other studies underscore its efficacy in pain management without contributing to dependency issues, paving the way for a new class of treatments for epilepsy and pain.
Funding Initiatives and Capital Allocation
Capital raising has remained a challenge, but we are thrilled to announce our recent securities offering with a target of raising up to $45 million through a Regulation D, Rule 506(c) exempt offering. This funding will be instrumental for our ongoing research and development projects across our subsidiaries, including ResolutionRx and EndeavourRx.
Our allocation plan emphasizes critical areas such as advancing our formulation of dronabinol for OSA and accelerating clinical development for ADHD treatments. Ensuring efficient management of these funds will enable us to push our innovative therapies from concept to reality.
Outlook for 2026 and Beyond
As we look toward 2026, our focus remains steadfast on building strong collaborations and improving our product pipeline. Discussions with strategic partners continue, and we are keen to expand our governance by appointing local professionals for ResolutionRx, enhancing our operational efficiency.
Moreover, our intellectual property portfolio is set for expansion, ensuring that we protect innovations while addressing critical conditions affecting millions worldwide.
A Heartfelt Appreciation to Our Supporters
In closing, we extend our deepest gratitude to all our shareholders, partners, and stakeholders for their unwavering support and belief in our vision. Your trust and engagement are invaluable as we strive to deliver transformative therapies that address the pressing needs of patients navigating complex health challenges.
With your support, we are confident we can achieve remarkable advancements in the health and wellness of our global community.
Frequently Asked Questions
What is RespireRx Pharmaceuticals focused on?
RespireRx Pharmaceuticals focuses on the development of innovative treatments for neurological and psychiatric disorders, including epilepsy, ADHD, and OSA.
How has the company progressed in 2025?
In 2025, the company achieved significant scientific milestones, including published studies and obtaining funding for clinical trials, particularly surrounding AMPAkines and GABAkines.
What are the future goals for RespireRx?
The company aims to expand its product pipeline, increase collaborations, and enhance its intellectual property portfolio to drive innovation in treatment options.
What is the current funding strategy?
RespireRx is conducting a Regulation D offering with a goal of raising up to $45 million to support its ongoing clinical and research initiatives across its subsidiaries.
Where can I learn more about their projects?
For more information, visit the respective websites of RespireRx, EndeavourRx, and ResolutionRx.
